about
Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey.Fibrolamellar hepatocellular carcinoma in an infant and literature review.Use of angioembolization as an effective technique for the management of pediatric solid tumors.Low-grade gliomas in children: single institutional experience in 198 cases.Safety of bevacizumab in patients younger than 4 years of age.Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.Epstein-Barr virus related opsoclonus-myoclonus-ataxia does not rule out the presence of occult neuroblastic tumors.Treatment of disseminated paraganglioma with gemcitabine and docetaxel.Treatment of childhood astrocytomas with irinotecan and cisplatin.Antiangiogenic treatment as a pre-operative management of alveolar soft-part sarcoma.Axenfeld-Rieger ocular anomaly and retinoblastoma caused by constitutional chromosome 13q deletion.Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study.Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells.Immunohistochemical analyses of alpha1 and alpha3 Na+/K+-ATPase subunit expression in medulloblastomas.Landscape of early clinical trials for childhood and adolescence cancer in SpainALK2 inhibitors display beneficial effects in preclinical models of mutant diffuse intrinsic pontine gliomaResults of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastomaIntra-arterial chemotherapy for retinoblastoma. Challenges of a prospective study
P50
Q36705927-924418C7-E5C7-4400-A32C-E047F61C5693Q37365116-BC9D41C9-B25E-49A6-B536-94BE9BB28863Q37593240-B11986E6-EB53-47B1-8263-70F621846C23Q38544218-9E90789D-83AD-4AC3-88DC-2F0C265D06ECQ38575870-F981BF7C-3641-4099-BDFE-F120FCBDE9F3Q39866458-E838916C-A66E-4957-A079-E019A2A62E50Q43281721-2A9660BC-869F-4C65-8079-011ACCF7824EQ45423560-479E595A-7A45-46E6-BA60-5A3E4BB4FC43Q46030841-6B0E0BC9-691B-44CE-98DC-DA9FC27BCDBEQ48204130-1D6D467E-F967-402A-A6B2-54823C79B062Q48632325-F41F57AC-9F23-4D97-A220-3A494F224EC8Q51602482-A276AE98-B809-4C73-A341-CE874AE01661Q51613326-9C7F5ED6-A301-4F4B-B7B5-4E4A92FAACA1Q55456542-86FC5F34-FEFF-43EC-BCF9-8C504626BC32Q55463202-53F792F6-F9A6-46F3-B1DB-DB2BB991C6EAQ57906735-9F0DC7E5-77EC-4733-BD0D-3944AC568E53Q64059831-BDA3FDCD-CF9C-42BB-85EF-D446937B3AAEQ73271601-5D17E9C8-DD6F-4EAA-A3C7-F20E9ACF016EQ87969501-E093764C-73A1-49B7-8B4F-0858AF82407B
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ofelia Cruz
@ast
Ofelia Cruz
@en
Ofelia Cruz
@es
Ofelia Cruz
@nl
type
label
Ofelia Cruz
@ast
Ofelia Cruz
@en
Ofelia Cruz
@es
Ofelia Cruz
@nl
prefLabel
Ofelia Cruz
@ast
Ofelia Cruz
@en
Ofelia Cruz
@es
Ofelia Cruz
@nl
P106
P31
P496
0000-0001-7102-3283